Home >> Research Area >>Neuroscience>>Dopamine Receptor>> OSU 6162 hydrochloride

OSU 6162 hydrochloride

Dopamine stabilizer CAS# 156907-84-5

OSU 6162 hydrochloride

Catalog No. BCC7424----Order now to get a substantial discount!

Product Name & Size Price Stock
OSU 6162 hydrochloride: 5mg $92 In Stock
OSU 6162 hydrochloride: 10mg Please Inquire In Stock
OSU 6162 hydrochloride: 20mg Please Inquire Please Inquire
OSU 6162 hydrochloride: 50mg Please Inquire Please Inquire
OSU 6162 hydrochloride: 100mg Please Inquire Please Inquire
OSU 6162 hydrochloride: 200mg Please Inquire Please Inquire
OSU 6162 hydrochloride: 500mg Please Inquire Please Inquire
OSU 6162 hydrochloride: 1000mg Please Inquire Please Inquire
Related Products
  • PDK1 inhibitor

    Catalog No.:BCC1843
    CAS No.:1001409-50-2
  • GSK2334470

    Catalog No.:BCC4982
    CAS No.:1227911-45-6
  • Radicicol

    Catalog No.:BCC2131
    CAS No.:12772-57-5
  • BX-912

    Catalog No.:BCC1250
    CAS No.:702674-56-4

Quality Control of OSU 6162 hydrochloride

Number of papers citing our products

Chemical structure

OSU 6162 hydrochloride

3D structure

Chemical Properties of OSU 6162 hydrochloride

Cas No. 156907-84-5 SDF Download SDF
PubChem ID 9836644 Appearance Powder
Formula C15H24ClNO2S M.Wt 317.87
Type of Compound N/A Storage Desiccate at -20°C
Synonyms PNU 96391
Solubility Soluble to 100 mM in water and to 100 mM in DMSO
Chemical Name (3S)-3-(3-methylsulfonylphenyl)-1-propylpiperidine;hydrochloride
SMILES CCCN1CCCC(C1)C2=CC(=CC=C2)S(=O)(=O)C.Cl
Standard InChIKey LEMGVHZVBREXAD-PFEQFJNWSA-N
Standard InChI InChI=1S/C15H23NO2S.ClH/c1-3-9-16-10-5-7-14(12-16)13-6-4-8-15(11-13)19(2,17)18;/h4,6,8,11,14H,3,5,7,9-10,12H2,1-2H3;1H/t14-;/m1./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of OSU 6162 hydrochloride

DescriptionDopamine stabilizer; lacks high affinity for various neuroreceptors in vitro (Ki values are 447 and 1305 nM for D2 and D3 receptors respectively and > 1 μM for other targets). Exhibits high D2 receptor occupancy in vivo; highly active on dopamine synthesis and turnover. Induces stabilizing effects on psychomotor function in behavioral tests without inducing hypolocomotion or catalepsy.

OSU 6162 hydrochloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

OSU 6162 hydrochloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of OSU 6162 hydrochloride

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.1459 mL 15.7297 mL 31.4594 mL 62.9188 mL 78.6485 mL
5 mM 0.6292 mL 3.1459 mL 6.2919 mL 12.5838 mL 15.7297 mL
10 mM 0.3146 mL 1.573 mL 3.1459 mL 6.2919 mL 7.8649 mL
50 mM 0.0629 mL 0.3146 mL 0.6292 mL 1.2584 mL 1.573 mL
100 mM 0.0315 mL 0.1573 mL 0.3146 mL 0.6292 mL 0.7865 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on OSU 6162 hydrochloride

The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat.[Pubmed:16648369]

J Pharmacol Exp Ther. 2006 Aug;318(2):810-8.

"Dopamine stabilizers" are a new class of compounds that have the ability to reverse both hypo- as well as hyperdopaminergia in vivo. This class, exemplified by the phenylpiperidines (S)-(-)-3-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl)-piperidine [ACR16] although lacking high in vitro binding affinity for dopamine D2 receptor [(-)-OSU6162, Ki = 447 nM; ACR16, Ki > 1 microM], shows functional actions, suggestive of their interaction. Hence, we evaluated in vivo D2 occupancy of these agents in rats and correlated it to observed effects in a series of behavioral, neurochemical, and endocrine models relevant to the dopamine system and antipsychotic effect. Both (-)-OSU6162 and ACR16 showed robust dose-dependent striatal D2 occupancy with ED50 values of 5.27 and 18.99 mg/kg s.c., respectively, and functional assays showed no partial agonism. Over an occupancy range of 37 to 87% (3-60 mg/kg) for (-)-OSU6162 and 35 to 74% (10-60 mg/kg) for ACR16, we observed both inhibitory (amphetamine-induced locomotor activity) and stimulatory effects (in habituated rats). Haloperidol, over a similar occupancy range (33-78%), potently inhibited psychostimulant activity and induced catalepsy, but it failed to activate habituated animals. In the conditioned avoidance response assay, ACR16 was clearly more efficacious than (-)-OSU6162. In addition, both these compounds demonstrated significant preferential Fos induction in the nucleus accumbens compared with the dorsolateral striatum, a strong predictor of atypical antipsychotic efficacy. The results suggest that dopamine stabilizers exhibit locomotor stabilizing as well as antipsychotic-like effects, with low motor side effect liability, in a dose range that corresponds to high D2 in vivo occupancy.

PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease.[Pubmed:12384167]

Neuropharmacology. 2002 Oct;43(5):817-24.

PNU-96391A is a weak dopamine (DA) D(2) receptor antagonist with behavioral stabilizing properties. Previous experiments revealed that PNU-96391A antagonizes the expression of L-DOPA induced behavioral sensitization (dyskinesias) in lesioned primates without inducing akinesia or reducing the anti-Parkinsonian efficacy of L-DOPA. This study evaluated the ability of PNU-96391A to block the development of DA agonist-induced behavioral sensitization in rats with unilateral 6-OH-DA lesions of the median forebrain bundle. Repeated twice daily treatment with L-DOPA and the decarboxylase inhibitor benserazide (15 and 5 mg/kg, IP, respectively), or quinpirole (D(2)/D(3) agonist, 0.1 mg/kg, SC) increased the contralateral rotations measured on day 7 and 14 as compared to day 1. PNU-96391A (10-60 mg/kg, SC, bid.) antagonized the development of behavioral sensitization induced by both agonists. The basal activity of L-DOPA was not affected while a reduction of quinpirole-induced rotations was observed after 30-60 mg/kg, SC of PNU-96391A. Neurochemical analyses confirmed >99 % reductions of striatal DA levels, unilaterally. Concomitant treatment with PNU-96391A and L-DOPA did not affect plasma levels of PNU-96391A indicating that the effects observed are not related to pharmacokinetic interactions. These results suggest that PNU-96391A could be therapeutically useful to prevent the development of behavioral sensitization induced by DA agonists.

Keywords:

OSU 6162 hydrochloride,156907-84-5,PNU 96391,Natural Products,Dopamine Receptor, buy OSU 6162 hydrochloride , OSU 6162 hydrochloride supplier , purchase OSU 6162 hydrochloride , OSU 6162 hydrochloride cost , OSU 6162 hydrochloride manufacturer , order OSU 6162 hydrochloride , high purity OSU 6162 hydrochloride

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: